Targets › SLC18A1
1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Nov 2048.
[Isoform 1]: Electrogenic antiporter that exchanges one cationic monoamine with two intravesicular protons across the membrane of secretory and synaptic vesicles. Uses the electrochemical proton gradient established by the V-type proton-pump ATPase to accumulate high concentrations of monoamines inside the vesicles prior to their release via exocytosis. (UniProt, P54219)
Open in Phaseline: the race on SLC18A1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | [18F]-6F-DA Fluorine-18 labeled dopamine analog entering cells via norepinephrine transporter (NET) an | SLC6A2, SLC18A1 | Phase 1 | Pheochromocytoma | Nov 2048 |
Pheochromocytoma (1)
small molecule (1)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.